| 2023 | A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
| ESMO OPEN |
| 2023 | Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
| Cancer Treatment and Research Communications |
| 2023 | A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
| ESMO OPEN |
| 2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
| 2023 | Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
| JOURNAL OF THORACIC ONCOLOGY |
| 2023 | Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia | JOURNAL OF THORACIC ONCOLOGY |
| 2023 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
| LUNG CANCER |
| 2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
| 2023 | Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
| FRONTIERS IN ONCOLOGY |
| 2023 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
| ONCOLOGIST |
| 2023 | Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications
| CLINICAL LUNG CANCER |
| 2023 | The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2023 | Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
| NATURE COMMUNICATIONS |
| 2023 | A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation
| CANCER |
| 2023 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide
| FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY |
| 2023 | Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC | CLINICAL CANCER RESEARCH |
| 2023 | A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data | FUTURE ONCOLOGY |
| 2023 | Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2023 | Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors | TARGETED ONCOLOGY |
| 2023 | Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
| CANCER RESEARCH AND TREATMENT |
| 2022 | Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11) | CLINICAL LUNG CANCER |
| 2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |
| 2022 | Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis
| BIOORGANIC & MEDICINAL CHEMISTRY LETTERS |
| 2022 | Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) | EUROPEAN JOURNAL OF CANCER |
| 2022 | Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial | EUROPEAN JOURNAL OF CANCER |
| 2022 | Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation | EUROPEAN JOURNAL OF CANCER |
| 2022 | 2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) | EUROPEAN JOURNAL OF CANCER |
| 2022 | First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | Lazertinib: on the Way to Its Throne
| YONSEI MEDICAL JOURNAL |
| 2022 | Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
| CLINICAL LUNG CANCER |
| 2022 | Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1
| BIOMEDICINE & PHARMACOTHERAPY |
| 2022 | DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | CLINICAL CANCER RESEARCH |
| 2022 | A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer | EXPERT OPINION ON INVESTIGATIONAL DRUGS |
| 2022 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | CLINICAL LUNG CANCER |
| 2022 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
| JTO Clinical and Research Reports |
| 2022 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | LANCET ONCOLOGY |
| 2022 | Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
| THERANOSTICS |
| 2022 | Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial | JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2022 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
| CLINICAL CANCER RESEARCH |
| 2022 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
| CLINICAL CANCER RESEARCH |
| 2022 | Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
| CURRENT ONCOLOGY |
http://orcid.org/0000-0002-5562-270X
(7401747804)
